In a clinical trial of hospitalized patients in the United Kingdom, low-dose dexamethasone (a steroid) reduced deaths by one-third in ventilated patients and one-fifth in patients receiving oxygen only, the UK's National Institute for Health Research reported today. Sir Patrick Vallance, chief scientific adviser for the UK government, said the news was "particularly exciting as this is an inexpensive widely available medicine."

The study randomized more than 2,100 patients to receive dexamethasone 6 mg once per day for 10 days as part of a clinical trial testing a range of potential COVID-19 treatments in National Health Service hospitals. It found no benefit from the drug for patients who did not require respiratory support. The Oxford University researchers plan to publish the study details soon.   

Related News Articles

Headline
The Health Resources and Services Administration has extended to May 18 the deadline for health care providers who received Provider Relief Fund payments…
Perspective
Yesterday, our country surpassed a grim and somber milestone: 1 million COVID-19 deaths in the U.S.. America’s hospitals and health systems — and their…
Headline
As U.S. COVID-19 deaths today surpassed 1 million, the AHA, American Medical Association, and American Nurses Association continued to urge everyone who is…
Headline
The Health Resources and Services Administration yesterday released another $450 million in American Rescue Plan Act payments to rural health care providers to…
Headline
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen,…
Headline
The AHA and other national health care organizations yesterday urged Health and Human Services Secretary Xavier Becerra to maintain the public health emergency…